FDA expands device compatibility for Paradromics' brain-computer interface

Paradromics Inc. has received an FDA approval letter expanding the types of computing devices that can be used with its investigational brain-computer interface (BCI) platform, the company announced. The approval creates a pathway for the company to support compatible personal, internet-connected devices through Convey, its user-facing system for translating decoded neural intent into communication and computer control.

The expansion moves the platform beyond a company-provided computing environment and toward a system designed to work with the technology patients already use day to day. Once Paradromics completes an agreed-upon deployment and testing process, compatible personal devices — including laptops, tablets and phones — can be added without the company seeking FDA approval for each individual device.

"As we think about building BCI as a technology platform, we need to push for generalized connectivity," Matt Angle, PhD, founder and CEO of Paradromics, said in the announcement. "That means being able to connect with the products and technology that are already part of your life. This approval begins clearing the way toward a BCI platform that can move with the user rather than tethering him or her to a fixed computing environment."

Convey serves as the connection between decoded neural intent and the digital world, according to the company. Paradromics' neural decoding software processes brain signals to determine intended output, while Convey translates that output into communication and computer control across supported devices.

Company officials framed the immediate change as one of flexibility and internet connectivity, with longer-term implications for patient mobility. Future BCI users could rely on a range of personal computing setups — a device mounted to a wheelchair, a laptop used for work, a tablet carried around the home or a mobile device that travels with the user — under a platform Paradromics says is designed to adapt to patients' lives rather than define them.

"We live much of our lives online, and access to a personal device can mean the ability to work, communicate with family, manage daily activities and participate more fully in the world," William J. Marks Jr., MD, MS-HCM, chief clinical officer of Paradromics, said in the announcement. "Designing for that experience is an important part of translating BCI technology from a clinical research system into something that can ultimately support people in everyday life."

Paradromics is currently evaluating its BCI platform for restoring communication and computer control in people with severe motor impairment. The FDA-approved Connect-One Early Feasibility Study is assessing the company's Connexus BCI, including its ability to safely restore communication and enable computer-device control. The company said the expanded device pathway does not change the underlying clinical care model of the study, but gives it more flexibility to evaluate how BCI-enabled computer control could eventually function within patients' personal digital environments.

Paradromics, headquartered in Austin, Texas, says the Connexus BCI is designed to capture neural activity at the resolution of individual neurons and translate neural intent into speech, computer control, movement and other functions. Its initial clinical focus is restoring communication for people who have lost the ability to speak due to paralysis and other severe motor impairments, with the company describing plans to eventually support direct AI interaction, advanced prosthetics, sensory feedback and treatments for mental health and other neurological conditions.

Regulatory flexibility widens for connected medical technology

The Paradromics device pathway reflects a broader pattern in how the FDA is approaching connected and software-driven medical technology. Rather than requiring a new review for every hardware iteration or paired consumer device, the agency has increasingly built flexibility into approval frameworks for products that rely on data-sharing between a medical device and outside technology. That shift has shown up across device categories, including a wearable cardioverter defibrillator that pairs with a mobile app for real-time data sharing with health care providers, part of a wider move toward wearables built for daily-life integration rather than clinical-only use.

The same logic is playing out in AI-driven monitoring and care-coordination tools, where regulators have shown willingness to grant early pathways — including breakthrough designations — to platforms still being validated in real-world settings. One recent example is an FDA Breakthrough Device Designation supporting an AI-driven, physician-prescribed virtual assistant that follows clinical protocols and flags deviations to care teams during post-discharge recovery, part of a broader push to extend monitoring beyond the hospital and into patients' homes.

For neurotechnology specifically, this regulatory posture matters because BCI systems depend on continuous, high-bandwidth data exchange between implanted hardware and external computing environments. As more of these systems move from single-purpose clinical setups toward general-purpose connectivity, physicians overseeing severely disabled patients may increasingly need to understand not just the clinical mechanics of a device, but the digital ecosystem — personal devices, software updates, connectivity requirements — that keeps it functioning in a patient's everyday life.